

The background features a financial chart with a red overlay. The chart shows a line graph with a shaded area underneath, representing a portfolio's performance. The y-axis is labeled 'Share Price' and ranges from 250 to 350. The x-axis shows dates from 2013 to 2014. A callout box indicates a 'Change on day 32.30'. The chart is overlaid on a grid of financial data, including stock names like 'ImgnTech' and 'K+S', and various financial metrics.

PORTFOLIO REVIEW

Gold Diggers

Tristin Foster - Rachel Kloepfer
Alex Ramsay - Lars Thulin

11/18/2024

Investment Overview: Hold vs Sell

Sector Rotation Strategy



ICLR



PYPL



LULU



PATH



ALLY



MRVL




ZTS



SECTOR ROTATION STRATEGY: +31.25% & \$128,424

Investment Decision	Sell
Total Return	+31.25%
SPY Return	19.14%
Holding Period	329 Days
Portfolio Weight	7.96%
Stdev	31.47%
Beta	1.002577
Purchase Date	12/22/2023
Proposed Rebalance Date	3/22/2024
Actual Rebalance Date	4/4/2024
Proposed Sell Date	6/22/2024



Investment Thesis

In 2023 the fund decided to incorporate a business cycles strategy based on the thesis that the Leading Economic Indicator index (LEI), sector performance, and business cycle were correlated. They analyzed historical sector performance and conducted back –testing to identify sectors likely to outperform over the next 6 months.

The analysis involved correlating recent data with past business cycles, focusing on 6 periods most similar to the last 8 months and then projecting trends for the subsequent six months

Sell Reasoning

The strategy has passed its proposed sell date and is now out of date. Strategy was intended to target upcoming business cycle and research was only conducted for the 6-month interval. This means the holding strategy moving forward has no research supporting it



ICLR: 13 shares, \$2,465.32

Investment Decision	Sell
Total Return	-15.69%
Holding Period	2 yr 1 mo
1 year return	-28.96%
Weight Davidson Fund	3.9%
Stdev	4.122
Beta	1.25
Dividend Yield	0.0%
Weight Total Portfolio	0.16%

Business Description

ICON PLC is a global clinical R&D service in the pharmaceutical, biotechnology, and medical device industries. The company specializes in designing, managing, and conducting clinical trials to develop and approve new therapies and treatments.

Investment Thesis

2022-2023 analyst Abram Gubler decided to purchase ICLR because ICON maintained a strong brand reputation, decades of experience, a diversified portfolio of offerings, and a strong geographic footprint, that help it gain market share in the clinical research space. The fund purchased the stock near its six-month low.



Sell Reasoning

ICLR hasn't been properly evaluated in the last academic year, being incorrectly reported at a cost basis of \$8.21/share when it should have been \$224. This resulted in a recorded return of over 3000% which may have caused oversight of lack of actual positive earnings. Last quarter missed estimates on EPS and revenue is down YOY.



PYPL: 38 shares, \$3,261.54

Investment Decision	Hold
Total Return	-7.91%
Holding Period	2 yr 3 mo
1 year return	+51.43%
Weight Davidson Fund	4.9%
Stdev	4.287
Beta	1.44
Dividend Yield	0.0%
Weight Total Portfolio	0.19%

Business Description

PayPal Holdings is a leader in digital payments, offering secure, fast, and convenient solutions for individuals and businesses. Its platform enables online money transfers, e-commerce transactions, and payment processing across a wide range of industries.

Investment Thesis

2022-2023 analyst Caroline McDonough decided to invest because PYPL was trading at its lowest levels in over 5 years, having declined nearly 67% in 2022. However, its long-running experience in online payments was a unique asset has become more valuable as e-commerce expands. The company's scalable nature should allow it to improve margins over time.



Hold Reasoning

PYPL dipped to its 52-week low at the end of 2023 and has been slowly climbing back up since. Most recent earnings showed above-expected EPS and below-expected revenue growth. PYPL also owns Venmo, who's transaction growth and credit card product are expected to continue being a strong branch for PYPL.



LULU: 15 shares, \$4,800.15

Investment Decision	Hold
Total Return	-6.68%
Holding Period	2 yr 2 mo
1 year return	-25.64%
Weight Davidson Fund	7.22%
Stdev	4.386
Beta	1.24
Dividend Yield	0.0%
Weight Total Portfolio	0.3%

Business Description

Lululemon Athletica is a leading athletic apparel brand specializing in high quality athleisure/sport clothing and accessories for yoga, running, training, and casual wear.

Investment Thesis

2022-2023 analyst Jake Bisk decided to invest based on the company's growing adoption and new growth strategy aiming to double men's growth, double online sells, and quadruple international revenue by 2026.



Hold Reasoning

While Lululemon should be monitored due to its lack of high success in international market expansion that was promised in 2022, it still maintains a strong brand identity, market share, and has expanded into menswear. Next quarter earnings are highly anticipated as they compare to growing competitor On Holdings (ONON).



PATH 180 shares, \$2,226.60

Investment Decision	Hold
Total Return	-68.80%
Holding Period	2 yr 10 mo
1 year return	-32.39%
Weight Davidson Fund	3.81%
Stdev	7.349
Beta	0.87
Dividend Yield	0%
Weight Total Portfolio	0.14%



Business Description

The UiPath platform is seen as one of the most extensive platforms in the RPA industry. With tools to discover potential tasks that can be automated, build and manage software robots, engage with customers, help companies meet governance requirements, and track the effectiveness of UiPath's tools, the company provides a wide range of services.

Investment Thesis

2021-2022 analyst Logan Ferguson invested in UiPath as the company was trading at all-time lows. The investment thesis was driven by three considerations: industry tailwinds, the company's growth at scale, and the platform's extensive offerings

Hold Reasoning

In 2024, PATH remains a leader in the RPA space with strong growth potential driven by its shift to AI-powered automation and cloud-based solutions. The company's large diversified customer base across industries like finance and healthcare positions is well to capitalize on increasing demand for automation. With improving financial metrics and a focus on sustainable growth, PATH offers promising long-term value, classified as a value stock.



ALLY 90 shares, \$3,440.50

Investment Decision	Hold
Total Return	-21.96%
Holding Period	2 yr 10 mo
1 year return	34.93%
Weight Davidson Fund	5.89%
Stdev	5.225
Beta	1.4
Dividend Yield	3.27%
Weight Total Portfolio	0.22%



Business Description

Ally Financial is a digital-first industrial bank which offers consumer and business focused financial products. The company is well known for being involved in the auto loan industry, offering services which help auto dealers finance customers on the spot, and its high-yield online savings accounts.

Investment Thesis

2021 to 2022 analyst Nick Tygesen invested in Ally Financial as part of a diversification play due to the fund being heavily underexposed to the financial industry as well as interest rates at the time rising which meant spreads between borrowing and lending rates widened.

Hold Reasoning

In 2024, with rates starting to decline, ALLY's consistent dividend payout and significant drop from 2022 highs position it as a value stock. Its exposure to the financial sector could enhance its appeal if rate cuts continue.



MRVL 100 shares, \$8,783.00

Investment Decision	Hold
Total Return	+88.67%
Holding Period	2 yr 2 mo
1 year return	+68.51%
Weight Davidson Fund	13.21%
Stdev	6.189
Beta	1.44
Dividend Yield	0.26%
Weight Total Portfolio	0.52%



Business Description

Marvell Technology is designer of semiconductors. Marvell serves multiple industries including enterprise networking, carrier infrastructure, automotive, and data centers. They have a global presence including operations in China, Singapore, and the United States.

Investment Thesis

2022 to 2023 analyst Tyler Young invested in MRVL. The company was added to the fund due to its strong revenue growth and financial position. The high demand for chips, variety of end markets, and the companies competitive positioning all made for an attractive investment. Analyst believed that market demand would rise over time as infostructure for widespread 5G was built out.

Hold Reasoning

The growing need for semiconductors and the diverse markets in which they are utilized provide Marvell with continual room for growth. In the previous two quarters they met and slightly exceeded analyst EPS predictions. Earlier this year the company signed contracts with Google and Amazon to produce technology that would assist in their AI offerings.



ZTS 25 shares, \$4,378.50

Investment Decision	Hold
Total Return	+9.24%
Holding Period	1 yr 9 mo
1 year return	+4.86%
Weight Davidson Fund	6.49%
Stdev	3.403
Beta	0.90
Dividend Yield	0.98%
Weight Total Portfolio	0.26%

1D | 5D | 1M | 6M | YTD | 1Y | **5Y** | Max



Business Description

Zoetis is the world's largest producer of medicine and vaccinations for pets and livestock. The company specializes in products for dogs, cats, horses, cattle and more. The company spunoff from Pfizer and became independent in 2013.

Investment Thesis

2022-2023 analyst Spencer Fletcher decided to purchase ZTS. The company invested in because of its market dominance and diverse offerings alongside it's growth potential. ZTS is valued highly within the industry due to their sole focus on animal health and direct relationships with customers

Hold Reasoning

ZTS continuous to be a dominant player in the animal health space currently holding 35.5% of the market. They have shown consistent growth over the past five years. They're gross profit has increased each year over this time for a total increase of 43.45%. In the past three quarters they have increased EPS. The industry is expected to grow at a steady rate of 3.1% over the next five years.



Conclusion

Sector Rotation Strategy



ICLR



PYPL



LULU



PATH



ALLY



MRVL



ZTS

